TG103
GLP-1 · s.c. · CSPC
Summary
- Also known as
- CSPC
- Mechanism
- GLP-1
- Route
- s.c.
- Company
- CSPC
- Highest development stage
- filed
- Status (as of data cut)
- Efmedaglutide alfa. Phase 3 T2D non-inferior to dulaglutide; obesity NDA accepted in China (Oct 2025) verify
- Next milestone
- China approval
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Obesity NDA accepted in China (Oct 2025); phase 3 numbers not published | CSPC announcement (Oct 2025) |
| T2D | 3 positive phase 3 | Phase 3 non-inferiority versus dulaglutide met | TG103 vs dulaglutide (EASD 2026) |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase III TG103 + metformin vs dulaglutide (EASD 2026) | 15 mg QW vs dulaglutide 1.5 mg QW (active comparator): HbA1c -1.25 | t2d china | 52 | 211 | — | — | −1.3 | — | — | — | — | — | — | press release |
| TG103 phase 3 vs dulaglutide (T2D) | TG103 15 mg vs dulaglutide: HbA1c −1.38 % | t2d china | 28 | — | — | — | −1.4 | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- 15 mg QW · hba1c · HKEX filing
Injection 15 mg group was higher than that in the dulaglutide 1.5 mg group (1.31% vs 1.25%),
Registered trials (3)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT06235086 A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2024-04 → 2026-02 | 632 | Completed; results not in the atlas yet | NCT06235086 |
| NCT06258148 A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus | T2D | Phase 3 | completed | 2024-04 → 2026-01 | 465 | Completed; results not in the atlas yet | NCT06258148 |
| NCT05997576 A Study of TG103 Injection in Non-diabetic Overweight or Obesity | Obesity | Phase 3 | completed | 2023-11 → 2025-02 | 675 | Completed; results not in the atlas yet | NCT05997576 |
Primary sources
- Xiaoling Cai et al. Efficacy and safety of TG103 versus dulaglutide as an add-on to metformin in patients with type 2 diabetes: a randomised Phase III trial. Abstract 836. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: SO 075 New drugs and new data]
- CSPC. CSPC voluntary announcement: Results of Phase III study of Efmedaglutide Alfa (TG103) + metformin in Chinese adults with T2DM presented at EASD 2026 [HKEX filing]. 2026-09-30. Available from: https://doc.irasia.com/listco/hk/cspc/announcement/a260930.pdf
How to cite this page
Cite the primary publication for any single result; every value above links to it.